PT3340973T - Sais farmaceuticamente aceitáveis de ácido beta-guanidinopropiónico com propriedades melhoradas e seus usos - Google Patents
Sais farmaceuticamente aceitáveis de ácido beta-guanidinopropiónico com propriedades melhoradas e seus usosInfo
- Publication number
- PT3340973T PT3340973T PT168401040T PT16840104T PT3340973T PT 3340973 T PT3340973 T PT 3340973T PT 168401040 T PT168401040 T PT 168401040T PT 16840104 T PT16840104 T PT 16840104T PT 3340973 T PT3340973 T PT 3340973T
- Authority
- PT
- Portugal
- Prior art keywords
- pharmaceutically acceptable
- acceptable salts
- improved properties
- guanidinopropionic acid
- guanidinopropionic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562209624P | 2015-08-25 | 2015-08-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3340973T true PT3340973T (pt) | 2021-01-19 |
Family
ID=58100994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT168401040T PT3340973T (pt) | 2015-08-25 | 2016-08-25 | Sais farmaceuticamente aceitáveis de ácido beta-guanidinopropiónico com propriedades melhoradas e seus usos |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20170056352A1 (enExample) |
| EP (1) | EP3340973B1 (enExample) |
| JP (2) | JP6880023B2 (enExample) |
| KR (1) | KR102707964B1 (enExample) |
| CN (2) | CN108472269B (enExample) |
| AU (1) | AU2016311368B2 (enExample) |
| CA (1) | CA2996520C (enExample) |
| DK (1) | DK3340973T3 (enExample) |
| ES (1) | ES2843561T3 (enExample) |
| HR (1) | HRP20210044T1 (enExample) |
| HU (1) | HUE053963T2 (enExample) |
| PL (1) | PL3340973T3 (enExample) |
| PT (1) | PT3340973T (enExample) |
| RS (1) | RS61804B1 (enExample) |
| SI (1) | SI3340973T1 (enExample) |
| WO (1) | WO2017035331A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3137447B1 (en) | 2014-04-30 | 2021-06-30 | Rgenix, Inc. | Inhibitors of creatine transport and uses thereof |
| WO2016100619A2 (en) * | 2014-12-17 | 2016-06-23 | Rgenix, Inc. | Treatment and diagnosis of cancer |
| US20170056352A1 (en) * | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| WO2018160178A1 (en) * | 2017-03-01 | 2018-09-07 | Rgenix, Inc. | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof |
| EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
| CA3161341A1 (en) | 2019-12-11 | 2021-06-17 | Masoud Fakhr Tavazoie | Methods of treating cancer |
| JP7689964B2 (ja) | 2019-12-13 | 2025-06-09 | インスピルナ，インコーポレーテッド | 金属塩及びその使用 |
| KR102615692B1 (ko) | 2021-10-13 | 2023-12-19 | 주식회사 휴엔켐 | 베타-구아니디노프로피온산을 포함하는 간섬유화 예방 또는 치료용 조성물 |
| EP4511349A1 (en) * | 2022-04-21 | 2025-02-26 | Merck Sharp & Dohme LLC | Process for preparing agglomerated crystalline medium-chain fatty acid sodium salts |
| KR102822799B1 (ko) | 2022-11-09 | 2025-06-20 | 충남대학교산학협력단 | 베타-구아니디노프로피온산을 포함하는 장내 미생물 개선용 조성물 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA101653A (en) | 1906-08-30 | 1906-10-23 | Herman Besser | Mould |
| BE794886A (fr) * | 1972-02-22 | 1973-08-02 | Pfizer | Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques |
| US3933797A (en) * | 1972-02-22 | 1976-01-20 | Pfizer Inc. | 6-[α-(ω-QUANIDINOALKANOYLAMIDO)ACYLAMIDO]PENICILLANIC ACIDS |
| US3972872A (en) | 1974-09-23 | 1976-08-03 | Pfizer Inc. | 6-[α-(ω-Guanidinoalkanoylamido)acylamido]penicillanic acids |
| KR960004900B1 (ko) | 1986-09-10 | 1996-04-17 | 신텍스(유.에스.에이.) 인코포레이티드 | 디아민의 선택적 아미딘화 방법 |
| US5676978A (en) * | 1989-02-14 | 1997-10-14 | Amira, Inc. | Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent |
| CA2028593C (en) * | 1989-10-31 | 2007-08-21 | Douglas R. Brandt | Stabilized enzyme compositions |
| DE4334639A1 (de) | 1993-10-11 | 1995-04-13 | Inst Neue Mat Gemein Gmbh | Verfahren zur Herstellung von TiN-Sinterkörpern und -Schichten |
| PT793646E (pt) | 1994-11-23 | 2002-03-28 | Biovitrum Ab | Carboxilatos de aminoguanidina destinados ao tratamento de diabetes mellitus nao-insulinodependente |
| US5994577A (en) | 1994-11-23 | 1999-11-30 | Larsen; Scott D. | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus |
| JP3745439B2 (ja) | 1995-07-06 | 2006-02-15 | 花王株式会社 | 皮膚外用剤 |
| TW453881B (en) | 1995-10-16 | 2001-09-11 | Kao Corp | Cosmetic composition comprising amide derivatives |
| JPH09202710A (ja) * | 1995-11-20 | 1997-08-05 | Kao Corp | しわ改善剤 |
| EP0912523A1 (en) | 1996-05-21 | 1999-05-06 | PHARMACIA & UPJOHN COMPANY | Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus |
| JP4317599B2 (ja) | 1996-06-26 | 2009-08-19 | 武田薬品工業株式会社 | 徐放性製剤 |
| DK1093370T3 (da) | 1998-06-30 | 2006-05-22 | Takeda Pharmaceutical | Farmaceutisk præparat til behandling af diabetes |
| EP1656945A1 (en) | 1999-06-05 | 2006-05-17 | The Board Of Trustees Of The Leland Stanford Junior University | Pharmaceutical composition comprising oligoarginine |
| US6605115B1 (en) | 1999-06-05 | 2003-08-12 | Board Of Trustees Of The Leland Stanford Junior University | Method and composition for inhibiting cardiovascular cell proliferation |
| US6242491B1 (en) | 1999-06-25 | 2001-06-05 | Rima Kaddurah-Daouk | Use of creatine or creatine compounds for skin preservation |
| US20020082448A1 (en) | 1999-11-08 | 2002-06-27 | The Upjohn Company | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus |
| CA2456964A1 (en) | 2001-08-08 | 2003-02-20 | Merck & Co., Inc. | Melanin-concentrating hormone antagonists |
| JP2005518346A (ja) | 2001-11-07 | 2005-06-23 | メディカル リサーチ カウンセル | ドパミン作動性ニューロンの調節 |
| CA2473229A1 (en) | 2002-01-09 | 2003-07-24 | Merck & Co., Inc. | Selective melanin-concentrating hormone type -1 receptor agonists |
| US20120245211A1 (en) | 2002-06-04 | 2012-09-27 | Children's Hospital Medical Center | Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism |
| EP1567180A4 (en) | 2002-06-04 | 2010-03-10 | Avicena Group Inc | METHOD FOR THE TREATMENT OF COGNITIVE DYSFUNCTION BY MODULATING THE CHANGE OF ENERGY REPLACEMENT IN THE BRAIN |
| GB0302882D0 (en) | 2003-02-07 | 2003-03-12 | Univ Cardiff | Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss |
| EP1746099A1 (en) | 2004-12-23 | 2007-01-24 | DeveloGen Aktiengesellschaft | Mnk1 or Mnk2 inhibitors |
| JP4865251B2 (ja) | 2005-05-09 | 2012-02-01 | 株式会社 資生堂 | 不全角化抑制剤、毛穴縮小剤及び皮膚外用組成物 |
| EP1909601B1 (de) | 2005-08-02 | 2013-05-22 | AlzChem Trostberg GmbH | Flüssig-formulierung auf basis einer guanidinoessigsäure-komponente |
| WO2008054544A2 (en) | 2006-05-22 | 2008-05-08 | Immune Disease Institute, Inc. | Method for delivery across the blood brain barrier |
| WO2008043024A2 (en) | 2006-10-04 | 2008-04-10 | Kalypsys, Inc. | Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease |
| BRPI0720105A2 (pt) | 2006-12-11 | 2014-10-07 | Kempharm Inc | Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos |
| DE102007004781A1 (de) | 2007-01-31 | 2008-08-07 | Alzchem Trostberg Gmbh | Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels |
| BRPI0807157A2 (pt) | 2007-02-08 | 2014-04-29 | Kempharm Inc | Pró-farmacos hidrófilos polares de anfetamina e outros estimulantes e processos para fabricação e uso dos mesmos |
| EP2197890A1 (en) | 2007-09-07 | 2010-06-23 | Gencia Corporation | Mitochondrial compositions and uses thereof |
| WO2009098142A1 (en) | 2008-02-06 | 2009-08-13 | Helm Ag | Prasugrel salts with improved properties |
| FR2940077B1 (fr) | 2008-12-19 | 2012-07-20 | Oreal | Procede de coloration eclaircissante de matieres keratiniques mettant en oeuvre une composition anhydre colorante comprenant un agent alcalin et une composition oxydante. |
| JP5711883B2 (ja) | 2008-12-19 | 2015-05-07 | ロレアル | 脂肪物質に富む水性組成物の存在下で、淡色化し、あるいは淡色化直接染色し、あるいは酸化染色する方法、及びそのためのデバイス |
| FR2940104B1 (fr) | 2008-12-19 | 2011-08-19 | Oreal | Procede de traitement des cheveux mettant en oeuvre une emulsion directe comprenant un agent oxydant et une composition contenant un agent alcalin |
| JP5866137B2 (ja) | 2009-04-30 | 2016-02-17 | ロレアル | アミノトリアルコキシシランまたはアミノトリアルケニルオキシシラン化合物を含む組成物を用いたヒトケラチン繊維の明色化および／または着色ならびに装置 |
| WO2011031308A1 (en) | 2009-09-09 | 2011-03-17 | Cytokinetics, Incorporated | Novel combinations |
| EP2477643A1 (en) | 2009-09-18 | 2012-07-25 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| FR2954160B1 (fr) | 2009-12-22 | 2012-03-30 | Oreal | Composition de coloration ou d'eclaircissement comprenant un corps gras et un polymere amphotere |
| CA2785846C (en) | 2009-12-31 | 2015-07-07 | Kempharm, Inc. | Amino acid conjugates of quetiapine, process for making and using the same |
| DE102010012199A1 (de) | 2010-03-19 | 2011-09-22 | Fresenius Medical Care Deutschland Gmbh | Molekular geprägte Polymere für die Eliminierung von Metaboliten |
| FR2958161B1 (fr) | 2010-04-02 | 2012-04-27 | Oreal | Procede de traitement des cheveux mettant en oeuvre une emulsion directe comprenant un agent oxydant et une emulsion directe contenant un agent alcalin |
| ES2713873T3 (es) | 2010-04-16 | 2019-05-24 | Nuevolution As | Complejos bifuncionales y métodos para hacer y utilizar tales complejos |
| US20110262359A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof |
| US20110262355A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
| EP2560490A1 (en) | 2010-04-21 | 2013-02-27 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof |
| EP2560489A4 (en) | 2010-04-21 | 2014-01-22 | Signature Therapeutics Inc | COMPOSITIONS WITH ENZYMSPALTBAR OPIOID PRODRUGS AND HEMMER FOR THIS |
| WO2011133348A1 (en) | 2010-04-21 | 2011-10-27 | Pharmacofore, Inc. | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof |
| RU2012151500A (ru) | 2010-05-03 | 2014-06-10 | Дженентек, Инк. | Композиции и способы, пригодные для снижения вязкости белковосодержащих составов |
| US20130281410A1 (en) | 2010-05-13 | 2013-10-24 | University Of Utah Research Foundation | Methods for the treatment of psychiatric disorders |
| EP2399885A1 (en) | 2010-06-22 | 2011-12-28 | Ulrich Dietz | Device and method for solubilizing, separating, removing and reacting carboxylic acids in aqueous or organic solutions by means of micro- or nanoemulsification |
| WO2012024611A1 (en) | 2010-08-20 | 2012-02-23 | Natural Alternatives International, Inc. | Methods of treating sarcopenia and frailty |
| WO2012047630A2 (en) | 2010-09-27 | 2012-04-12 | Martin Teintze | N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use |
| US8765115B2 (en) | 2010-12-01 | 2014-07-01 | National Institute of Agrobiological Scienses | Method of treatment of gastrointestinal disorders with IL-10 |
| BR112013022946A2 (pt) | 2011-03-09 | 2017-07-18 | Signature Therapeutics Inc | pró-fármacos de agentes ativos com ligantes heterocíclocos |
| WO2012122420A2 (en) | 2011-03-09 | 2012-09-13 | Pharmacofore, Inc. | Opioid prodrugs with heterocyclic linkers |
| US20120232066A1 (en) | 2011-03-09 | 2012-09-13 | Jenkins Thomas E | Compositions for reducing risk of adverse events caused by drug-drug interactions |
| WO2012138214A1 (en) | 2011-04-08 | 2012-10-11 | Brewster Lizzy Maritza | Beta-guanidinopropionic acid for the treatment of hypertension |
| WO2012173846A2 (en) | 2011-06-06 | 2012-12-20 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| CN102850242A (zh) * | 2011-06-27 | 2013-01-02 | 天津天成制药有限公司 | 胍基丙酸硝酸盐的制备方法 |
| US8427223B2 (en) | 2011-07-19 | 2013-04-23 | Lsi Corporation | Voltage level translator circuit for reducing jitter |
| MY162499A (en) | 2011-07-28 | 2017-06-15 | Kempharm Inc | Methylphenidate-prodrugs, processes of making and using the same |
| CN104039342A (zh) | 2011-10-18 | 2014-09-10 | 爱勒让治疗公司 | 拟肽大环化合物 |
| FR2983407B1 (fr) | 2011-12-06 | 2014-01-03 | Oreal | Composition aqueuse riche en huile et son utilisation dans un procede de coloration d'oxydation ou de decoloration |
| NZ627528A (en) | 2012-02-15 | 2016-05-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| AU2013273138B2 (en) | 2012-06-05 | 2017-06-15 | Neuroderm Ltd | Compositions comprising apomorphine and organic acids and uses thereof |
| WO2013189910A1 (en) | 2012-06-22 | 2013-12-27 | Basf Se | Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers |
| CN114306315A (zh) | 2012-10-31 | 2022-04-12 | 洛克菲勒大学 | 结肠癌的治疗和诊断 |
| FR2997846B1 (fr) | 2012-11-09 | 2023-10-20 | Oreal | Composition comprenant un derive dicarbonyle et un acide, le procede de lissage des fibres keratiniques a partir de cette composition |
| WO2014138492A1 (en) | 2013-03-08 | 2014-09-12 | Solan, LLC | Methods for fabricating graphite-based structures and devices made therefrom |
| CN103288685B (zh) * | 2013-07-03 | 2015-02-18 | 郭礼强 | 一种3-胍基丙酸的制备方法 |
| US20170056352A1 (en) | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
| WO2018160178A1 (en) | 2017-03-01 | 2018-09-07 | Rgenix, Inc. | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof |
-
2016
- 2016-08-24 US US15/245,750 patent/US20170056352A1/en not_active Abandoned
- 2016-08-25 ES ES16840104T patent/ES2843561T3/es active Active
- 2016-08-25 CN CN201680057402.2A patent/CN108472269B/zh active Active
- 2016-08-25 EP EP16840104.0A patent/EP3340973B1/en active Active
- 2016-08-25 AU AU2016311368A patent/AU2016311368B2/en active Active
- 2016-08-25 WO PCT/US2016/048643 patent/WO2017035331A1/en not_active Ceased
- 2016-08-25 DK DK16840104.0T patent/DK3340973T3/da active
- 2016-08-25 KR KR1020187008144A patent/KR102707964B1/ko active Active
- 2016-08-25 PL PL16840104T patent/PL3340973T3/pl unknown
- 2016-08-25 HU HUE16840104A patent/HUE053963T2/hu unknown
- 2016-08-25 JP JP2018529503A patent/JP6880023B2/ja active Active
- 2016-08-25 CN CN202111189796.6A patent/CN114057611A/zh active Pending
- 2016-08-25 PT PT168401040T patent/PT3340973T/pt unknown
- 2016-08-25 CA CA2996520A patent/CA2996520C/en active Active
- 2016-08-25 HR HRP20210044TT patent/HRP20210044T1/hr unknown
- 2016-08-25 RS RS20210023A patent/RS61804B1/sr unknown
- 2016-08-25 SI SI201631048T patent/SI3340973T1/sl unknown
- 2016-09-30 US US15/281,329 patent/US9827217B2/en active Active
-
2017
- 2017-10-27 US US15/795,540 patent/US10512623B2/en active Active
-
2019
- 2019-11-06 US US16/675,669 patent/US20200138759A1/en not_active Abandoned
-
2021
- 2021-04-30 JP JP2021077099A patent/JP7134294B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114057611A (zh) | 2022-02-18 |
| JP6880023B2 (ja) | 2021-06-02 |
| ES2843561T3 (es) | 2021-07-19 |
| DK3340973T3 (da) | 2021-01-11 |
| AU2016311368A1 (en) | 2018-03-29 |
| HUE053963T2 (hu) | 2021-07-28 |
| US9827217B2 (en) | 2017-11-28 |
| KR102707964B1 (ko) | 2024-09-20 |
| AU2016311368B2 (en) | 2020-10-08 |
| JP7134294B2 (ja) | 2022-09-09 |
| JP2021121597A (ja) | 2021-08-26 |
| PL3340973T3 (pl) | 2021-06-14 |
| RS61804B1 (sr) | 2021-06-30 |
| SI3340973T1 (sl) | 2021-07-30 |
| US20180243248A1 (en) | 2018-08-30 |
| US10512623B2 (en) | 2019-12-24 |
| KR20180059446A (ko) | 2018-06-04 |
| HK1257822A1 (en) | 2019-11-01 |
| US20170056353A1 (en) | 2017-03-02 |
| CA2996520A1 (en) | 2017-03-02 |
| WO2017035331A1 (en) | 2017-03-02 |
| CA2996520C (en) | 2024-11-19 |
| CN108472269A (zh) | 2018-08-31 |
| JP2018531280A (ja) | 2018-10-25 |
| EP3340973A4 (en) | 2019-04-03 |
| EP3340973B1 (en) | 2020-10-14 |
| EP3340973A1 (en) | 2018-07-04 |
| CN108472269B (zh) | 2021-11-02 |
| US20170056352A1 (en) | 2017-03-02 |
| HRP20210044T1 (hr) | 2021-04-30 |
| US20200138759A1 (en) | 2020-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301217I2 (nl) | tirzepatide en farmaceutisch aanvaardbare zouten daarvan | |
| NO2022046I1 (no) | Berotralstat and pharmaceutically acceptable salts thereof | |
| NO2025015I1 (no) | Repotrectinib and/or pharmaceutically acceptable salts and esters thereof | |
| HUS2100006I1 (hu) | Avapritinib és gyógyászatilag elfogadható sói | |
| PT3340973T (pt) | Sais farmaceuticamente aceitáveis de ácido beta-guanidinopropiónico com propriedades melhoradas e seus usos | |
| ZA201608682B (en) | Boronic acid derivatives and therapeutic uses thereof | |
| SG11201803408PA (en) | Valbenazine salts and polymorphs thereof | |
| IL258922A (en) | Methods for the preparation of obeticholic acid and derivatives thereof | |
| IL251703B (en) | A pharmaceutical preparation with improved stability | |
| GB201619962D0 (en) | Synthetic acid compositions and uses thereof | |
| ZA201703398B (en) | Pharmaceutical composition and methods | |
| IL247978A0 (en) | Modified sulfamidase and its production | |
| ZA201607919B (en) | Dipicolylamine derivatives and their pharmaceutical uses | |
| EP3223817A4 (en) | Substantially pure vemurafenib and its salts | |
| IL248854B (en) | R-pyralindole and its pharmaceutically acceptable salts for use in medicine | |
| IL259073A (en) | History of abscisic acid - converted at the 3' position | |
| SG11201708527RA (en) | Manufacture of organopolysulfides and salts thereof | |
| HUE053181T2 (hu) | Gyógyszerészeti készítmény megnövelt oldékonysággal és stabilitással | |
| HK1263194A1 (en) | Analgesic preparation with nanocarriers and use thereof | |
| IL251930B (en) | Benzylhydroxy derivatives, their preparation and medical uses | |
| HK1260336A1 (en) | Valbenazine salts and polymorphs thereof | |
| GB201504142D0 (en) | Option administration |